Stockscreener 앱 받기
1.32
11.41%
-0.17
시간 외 거래:
1.33
0.01
+0.76%
전일 마감가:
$1.49
열려 있는:
$1.49
하루 거래량:
3.06M
Relative Volume:
2.09
시가총액:
$95.68M
수익:
-
순이익/손실:
$-44.95M
주가수익비율:
-1.479
EPS:
-0.8925
순현금흐름:
$-56.37M
1주 성능:
-27.87%
1개월 성능:
-23.70%
6개월 성능:
+8.20%
1년 성능:
-35.61%
1일 변동 폭
$1.303
$1.49
1주일 범위
$1.303
$1.85
52주 변동 폭
$0.8719
$2.99
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.32 | 95.68M | 0 | -44.95M | -56.37M | -0.8925 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Form 424B5 Biomea Fusion Inc For: 27 September By Investing.com - Investing.com Nigeria
BMEA Stock Slides As Biomea Fusion Pulls Equity Offering - timothysykes.com
Biomea Fusion Shares Fall 19% After Hours: Here’s Why - webull.com
Biomea Fusion scraps equity offering, delays study data - scanx.trade
Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA) - Seeking Alpha
Biomea Fusion Scraps Stock Offering, Sending Shares Down 19% After Hours - finance.biggo.com
Biomea Fusion Shares Fall After Terminating Proposed Public Offering - marketscreener.com
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - Benzinga
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next - TipRanks
Biomea stock slips after delaying trial readout (BMEA:NASDAQ) - Seeking Alpha
Biomea Fusion stock ticks up after canceling public offering By Investing.com - Investing.com Nigeria
Biomea Fusion stock ticks up after canceling public offering - Investing.com
Biomea Fusion terminates proposed public offering By Investing.com - Investing.com Canada
Biomea Fusion terminates proposed public offering - Investing.com
Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities - tradingview.com
Biomea Fusion Announces Termination of Proposed Public Offering of Securities - globenewswire.com
Biomea Fusion stock tumbles on public offering launch - Investing.com
Biomea Fusion stock tumbles on public offering launch By Investing.com - Investing.com Nigeria
Biomea Fusion Updates Timeline for BMF-650 Phase I Data - TipRanks
Biomea Fusion announces public offering of common stock - Investing.com
Biomea Fusion announces public offering of common stock By Investing.com - Investing.com Nigeria
Biomea Fusion Proposes Public Offering of Common Stock, Pre-Funded Warrants - marketscreener.com
Biomea Fusion Announces Proposed Public Offering of Securities - The Manila Times
Biomea Fusion announces proposed public offering of shares - tradingview.com
No size or terms are set for Biomea Fusion's share offering. Its underwriter may buy up to 15% more. - Stock Titan
BMEA Stock Price and Chart — NASDAQ:BMEA - TradingView
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from S&P Global BMI Index - marketscreener.com
Biomea Fusion Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock GainRevenue Recognition Risk - dars.gov.et
Biomea Fusion, Inc. (BMEA) Presents at H.C. Wainwright 28th Annual Global Investment ConferenceSlideshow (NASDAQ:BMEA) 2026-09-16 - Seeking Alpha
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Yahoo Finance
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks
Biomea Fusion to Participate in Upcoming Investor Conferences - Investing News Network
BMEA Surges 6.85%: Biomea Fusion Approaches Key $1.88 ResistanceQuote Data - vinanet.vn
Biomea Fusion (BMEA) Rallies 4.46% to $1.75 as Clinical-Stage Biotech Tests ResistanceSize Factor - dars.gov.et
BMEA Should I Buy - Intellectia AI
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation - Sahm
Biomea Shares Rise After Completing Enrollment in Diabetes Trial - marketscreener.com
Biomea Fusion stock surges on diabetes trial enrollment completion By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment By Investing.com - Investing.com UK
Why is Biomea Fusion stock climbing today? By Investing.com - Investing.com India
Biomea Fusion completes enrollment in diabetes trial By Investing.com - Investing.com Canada
Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes - TradingView
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - TradingView
Biomea (BMEA) Q2 2026 Results: EPS Prints Above Forecast in the Latest Session; Share Response: The Stock Records a 19.71% Increase for the Current SessionNegative Surprise Momentum - dars.gov.et
Biomea (BMEA) Quarterly Results: Profit Per Share Clears Its Benchmark at the Close; Investor Response - vinanet.vn
Biomea Fusion begins dosing first participant in OPAL study arm for new combination therapy - Traders Union
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - Kalkine Media
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - investingnews.com
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):